Board of Directors

Fredrik Hübinette

Chairman

Education: 

Born: 1969

Past experience: 20 years of experience from the pharmaceutical industry with research and development, production and marketing and sales in Wallac, Pharmacia and Orexo. Has invented and patented the form of preparation Karessa uses. Co-founder of four companies that work with the preparation form commercially, of which Karessa, Klaria and Nicoccino are listed on First North. Works as an advisor to these companies.

Other current engagements include: --

Shareholding: 1 003 878

Option holding: 0

Elected to the board since: 2019

Independent in relation to the company and the company management: No

Independent in relation to the company's major shareholders: No

Scott Boyer

Board member

Born: 1962

Education: PhD, University of Colorado, Boulder – Toxicology. NIH Fogarty International Centre Postdoctoral Fellow – Karolinska Institute

Other current engagements: Director – Computational Toxicology, Karolinska Institute, CEO, Klaria Pharmaceuticals AB

Previous directorships: -

Shareholding: 10,000

Option holding: 0

Elected to the board since: 2014

Independent in relation to the company and the company management: Yes

Independent in relation to the company's major shareholders: Yes

Stefan Arver

Board member

Born: 1952

Education: MD, PhD (Karolinska Institute), Registered medical practitioner, specialist in endocrinology

Other current engagements: Director European Academy of Andrology accredited Educational Centre in Andrology. Fellow and chief physician. Patient Flow manager ANOVA (Andrology, Sexual ­Medicine and Trans medicine) Karolinska University Hospital, Solna. Research group leader in Andrology, Sexual Medicine and Trans Medicine, Institue for Medicin Huddinge Karolinska Institute. Scientific adviser, consultant in the area of men's gender-specific diseases. Board member Acrosomen AB and Sarko AB, deputy board member Alabio AB.

Shareholding: 10,415

Option holding: 0

Elected to the board since: 2014

Independent in relation to the company and the company management: Yes

Independent in relation to the company's major shareholders: Yes

Kristina Lidén Mascher

Board member

Born: 1963

Education : Henley MBA, University of Reading, London, UK. Registered nurse, speciality oftalmology.   

Past experience: International Research manager, Pharmacia and Astra Zeneca. Director Clinical Research, Elekta and Medivir. Director QA, Melacure. Country manager, Remedium. Head of QA, Ganymed. 

Other current engagements:  Clinic and QA manager at Karessa on conultancy basis since 2016, member of the management team. Consultancy for Klaria Pharma. CEO and board member MAKK Consulting AB.

Shareholding: 8 720

Option holding: 0

Elected to the board since: 2019

Independent in relation to the company and the company management: No

Independent in relation to the company's major shareholders: Yes

Neal Meacham

Board member

Born: 1952

Education: Bachelor in sociology and antropology.

Other current engagements: Securities adviser to Securities Services at Swedbank AB (publ) focusing on product strategies and administrative services in the securities area.

Shareholding: 0

Option holding: 0

Elected to the board since: 2019

Independent in relation to the company and the company management: Yes

Independent in relation to the company's major shareholders: Yes